#ProfoundBio - Twitter Hashtag

9 months ago

$GMAB has stopped development of an early-stage PTK7-targeted #ADC GEN1107 (PRO1107) that it swooped up in its $1.8 billion acquisition of 🇨🇳 #ProfoundBio last year. https://t.co/ZNofzvdpHk The Danish biopharma ended clinical development of GEN1107, or PRO1107, “as the overall benefit-risk profile no longer supports continuation,” the company said Monday in an update to the Phase 1/2 trial registry. A Genmab spokesperson confirmed the decision. GEN1107 is one of multiple programs listed in a lawsuit brought by $ABBV earlier this year. The Chicago-area pharma giant is suing Genmab in federal court, alleging that ProfoundBio used proprietary information from one of AbbVie’s former scientists to create its ADCs. Genmab has refuted the allegations. The Genmab spokesperson declined to comment on the litigation.

0

17

3

2

8K

Bertrand Delsuc @BertrandBio

over 1 year ago

Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Ovarian & Endometrial Cancers in Phase 1/2 #ADC $GMAB #ProfoundBio (already posted this one as well - note the per BSA dosing, not per kg) https://t.co/F1lOi7y5Rp

1

8

1

2K

Bertrand Delsuc @BertrandBio

over 1 year ago

$GMAB #ProfoundBio Rina-S (FRa/TopoI with hydrophobicity masking tech) in EC/OC #ESMO24 2/2

2

5

1

2

3K

Bertrand Delsuc @BertrandBio

over 1 year ago

$GMAB #ProfoundBio Rina-S (FRa/TopoI with hydrophobicity masking tech) in (mainly Pt-resistant) EC/OC #ESMO24 1/2 delta ORR between 100 & 120mg/m2 certainly not real interesting activity in FRa<75% (current ELAHERE cutoff) short FU no ILD